Skip to content
Triangle logo TriangleGet started
← Study library

NCT02393248 · REGISTRY CONDITION SEARCH

Open-Label, Dose-Escalation Study of Pemigatinib in Subjects With Advanced Malignancies - (FIGHT-101)

Found through the registry condition index, not selected as a treatment recommendation. This discovery collection was restricted to studies with posted results.

Phase
PHASE1, PHASE2
Status at capture
TERMINATED
Registry last update
2023-01-06

The purpose of this study will be to evaluate the safety, tolerability, and pharmacological activity of pemigatinib in subjects with advanced malignancies. This study will have three parts, dose escalation (Part 1), dose expansion (Part 2) and combination therapy (Part 3).

Open the original ClinicalTrials.gov record → · Download preserved record

What did the study report?

Outcomes, safety and baseline populations are separate source sections. Quality-of-life measures appear under their original outcome titles.

flow

Participant flow

→

baseline

Baseline characteristics

→

outcome · POSTED

Parts 1 and 2 Combined: Number of Participants With Any Treatment-emergent Adverse Event (TEAE)

→

outcome · POSTED

Part 3: Number of Participants With Any TEAE

→

outcome · POSTED

E0 Following Once Daily Dosing of Pemigatinib as Monotherapy in Parts 1 and 2

→

outcome · POSTED

EC50 Following Once Daily Dosing of Pemigatinib as Monotherapy in Parts 1 and 2

→

outcome · POSTED

Emax Following Once Daily Dosing of Pemigatinib as Monotherapy in Parts 1 and 2

→

outcome · POSTED

Highest Serum Phosphate Concentration Following Pemigatinib as Monotherapy in Parts 1 and 2

→

outcome · POSTED

Part 2: Overall Response Rate (ORR)

→

outcome · POSTED

Part 3: ORR

→

outcome · POSTED

Parts 1 and 2: Cmax After Once Daily Dosing of Pemigatinib as Monotherapy on Cycle 1 Day 1

→

outcome · POSTED

Parts 1 and 2: Tmax After Once Daily Dosing of Pemigatinib as Monotherapy on Cycle 1 Day 1

→

outcome · POSTED

Parts 1 and 2: AUClast After Once Daily Dosing of Pemigatinib as Monotherapy on Cycle 1 Day 1

→

outcome · POSTED

Parts 1 and 2: AUC0-24 After Once Daily Dosing of Pemigatinib as Monotherapy on Cycle 1 Day 1

→

outcome · POSTED

Parts 1 and 2: Cmax After Once Daily Dosing of Pemigatinib as Monotherapy on Cycle 1 Days 8 and 14 (Steady State)

→

outcome · POSTED

Parts 1 and 2: Tmax After Once Daily Dosing of Pemigatinib as Monotherapy on Cycle 1 Days 8 and 14 (Steady State)

→

outcome · POSTED

Parts 1 and 2: t1/2 After Once Daily Dosing of Pemigatinib as Monotherapy on Cycle 1 Days 8 and 14 (Steady State)

→

outcome · POSTED

Parts 1 and 2: Cmin After Once Daily Dosing of Pemigatinib as Monotherapy on Cycle 1 Days 8 and 14 (Steady State)

→

outcome · POSTED

Parts 1 and 2: AUC0-24 After Once Daily Dosing of Pemigatinib as Monotherapy on Cycle 1 Days 8 and 14 (Steady State)

→

outcome · POSTED

Parts 1 and 2: CL/F After Once Daily Dosing of Pemigatinib as Monotherapy on Cycle 1 Days 8 and 14 (Steady State)

→

outcome · POSTED

Parts 1 and 2: Vz/F After Once Daily Dosing of Pemigatinib as Monotherapy on Cycle 1 Days 8 and 14 (Steady State)

→

outcome · POSTED

Parts 1 and 2: Accumulation Ratio After Once Daily Dosing of Pemigatinib as Monotherapy on Cycle 1 Days 8 and 14 (Steady State)

→

outcome · POSTED

Parts 1 and 2: Cmax Steady State Following Administration of Pemigatinib in the Fasted (Cycle 1 Day 14) and Fed (Cycle 2 Day 14) States

→

outcome · POSTED

Parts 1 and 2: Tmax Steady State Following Administration of Pemigatinib in the Fasted (Cycle 1 Day 14) and Fed (Cycle 2 Day 14) States

→

outcome · POSTED

Parts 1 and 2: t1/2 Steady State Following Administration of Pemigatinib in the Fasted (Cycle 1 Day 14) and Fed (Cycle 2 Day 14) States

→

outcome · POSTED

Parts 1 and 2: Cmin Steady State Following Administration of Pemigatinib in the Fasted (Cycle 1 Day 14) and Fed (Cycle 2 Day 14) States

→

outcome · POSTED

Parts 1 and 2: AUC0-24 Steady State Following Administration of Pemigatinib in the Fasted (Cycle 1 Day 14) and Fed (Cycle 2 Day 14) States

→

outcome · POSTED

Parts 1 and 2: CL/F Steady State Following Administration of Pemigatinib in the Fasted (Cycle 1 Day 14) and Fed (Cycle 2 Day 14) States

→

outcome · POSTED

Parts 1 and 2: Vz/F Steady State Following Administration of Pemigatinib in the Fasted (Cycle 1 Day 14) and Fed (Cycle 2 Day 14) States

→

outcome · POSTED

Part 3: Cmax of Pemigatinib as Part of Combination Therapy on Cycle 1 Day 1

→

outcome · POSTED

Part 3: Tmax of Pemigatinib as Part of Combination Therapy on Cycle 1 Day 1

→

outcome · POSTED

Part 3: AUClast of Pemigatinib as Part of Combination Therapy on Cycle 1 Day 1

→

outcome · POSTED

Part 3: AUC0-24 of Pemigatinib as Part of Combination Therapy on Cycle 1 Day 1

→

outcome · POSTED

Part 3: Cmax of Pemigatinib as Part of Combination Therapy on Cycle 1 Day 14 (Steady State)

→

outcome · POSTED

Part 3: Tmax of Pemigatinib as Part of Combination Therapy on Cycle 1 Day 14 (Steady State)

→

outcome · POSTED

Part 3: t1/2 of Pemigatinib as Part of Combination Therapy on Cycle 1 Day 14 (Steady State)

→

outcome · POSTED

Part 3: Cmin of Pemigatinib as Part of Combination Therapy on Cycle 1 Day 14 (Steady State)

→

outcome · POSTED

Part 3: AUC0-24 of Pemigatinib as Part of Combination Therapy on Cycle 1 Day 14 (Steady State)

→

outcome · POSTED

Part 3: CL/F of Pemigatinib as Part of Combination Therapy on Cycle 1 Day 14 (Steady State)

→

outcome · POSTED

Part 3: Vz/F of Pemigatinib as Part of Combination Therapy on Cycle 1 Day 14 (Steady State)

→

outcome · POSTED

Part 3: Accumulation Ratio of Pemigatinib as Part of Combination Therapy on Cycle 1 Day 14 (Steady State)

→

adverse events

Adverse events

→

more info

Limitations, agreements, and source contact

→
Who could take part
eligibility Criteria
Inclusion Criteria: 1. Male or female subjects, age 18 years or older on day of signing consent 2. Part 1: Any advanced solid tumor malignancy; Part 2: Subjects with squamous non-small cell lung cancer, cholangiocarcinoma/gastric cancer, urothelial cancer, breast/endometrial cancer, multiple myeloma, or MPNs that have a tumor or malignancy that has been evaluated and confirmed to harbor genetic alterations in FGF or FGFR genes. A subject's fibroblast growth factor (FGF) or fibroblast growth factor receptor (FGFR) alteration may be based on local or central laboratory results. Part 3: Dose finding: subjects with solid tumor malignancies who qualify for combo therapy; dose-expansion: FGF/FGFR+ subjects qualified to receive combo therapy 3. Has progressed after prior therapy and there is no further effective standard anticancer therapy available (including subject refuses or is intolerant) 4. Life expectancy \> 12 weeks 5. Eastern Cooperative Oncology Group (ECOG) performance status: * Part 1: 0 or 1 * Part 2 and 3: 0, 1, or 2 Exclusion Criteria: 1. Treatment with other investigational study drug for any indication for any reason, or receipt of anticancer medications within 21 days or 5 half-lives before first dose of study drug 2. Prior receipt of a selective FGFR inhibitor 3. History of a calcium/phosphate homeostasis disorder 4. History and/or current evidence of ectopic mineralization/calcification 5. Current evidence of corneal disorder/keratopathy 6. Has a history or presence of inadequate liver, renal, hematopoietic and/or cardiac function parameters outside protocol-defined range 7. Prior radiotherapy within 2 weeks of study treatment
healthy Volunteers
false
minimum Age
18 Years
sex
ALL
std Ages
  1. ADULT
  2. OLDER_ADULT
Treatment arms and interventions
arm Groups
  1. description
    Participants self-administered oral pemigatinib 1/2/4 milligrams (mg) once daily (QD) on a 2-weeks-on therapy and 1-week-off therapy schedule. The treatment cycle consisted of: Days 1 through 14: pemigatinib QD; Days 15 through 21: treatment break.
    intervention Names
    1. Drug: Pemigatinib
    label
    Part 1: Intermittent pemigatinib 1/2/4 mg QD
    type
    EXPERIMENTAL
  2. description
    Participants self-administered oral pemigatinib 6 mg QD on a 2-weeks-on therapy and 1-week-off therapy schedule. The treatment cycle consisted of: Days 1 through 14: pemigatinib QD; Days 15 through 21: treatment break.
    intervention Names
    1. Drug: Pemigatinib
    label
    Part 1: Intermittent pemigatinib 6 mg QD
    type
    EXPERIMENTAL
  3. description
    Participants self-administered oral pemigatinib 9 mg QD on a 2-weeks-on therapy and 1-week-off therapy schedule. The treatment cycle consisted of: Days 1 through 14: pemigatinib QD; Days 15 through 21: treatment break.
    intervention Names
    1. Drug: Pemigatinib
    label
    Part 1: Intermittent pemigatinib 9 mg QD
    type
    EXPERIMENTAL
  4. description
    Participants self-administered oral pemigatinib 13.5 mg QD on a 2-weeks-on therapy and 1-week-off therapy schedule. The treatment cycle consisted of: Days 1 through 14: pemigatinib QD; Days 15 through 21: treatment break.
    intervention Names
    1. Drug: Pemigatinib
    label
    Part 1: Intermittent pemigatinib 13.5 mg QD
    type
    EXPERIMENTAL
  5. description
    Participants self-administered oral pemigatinib 20 mg QD on a 2-weeks-on therapy and 1-week-off therapy schedule. The treatment cycle consisted of: Days 1 through 14: pemigatinib QD; Days 15 through 21: treatment break.
    intervention Names
    1. Drug: Pemigatinib
    label
    Part 1: Intermittent pemigatinib 20 mg QD
    type
    EXPERIMENTAL
  6. description
    Participants self-administered oral pemigatinib 9 mg QD on Days 1 through 21 of each 21-day cycle.
    intervention Names
    1. Drug: Pemigatinib
    label
    Part 1: Continuous pemigatinib 9 mg QD
    type
    EXPERIMENTAL
  7. description
    Participants self-administered oral pemigatinib 13.5 mg QD on Days 1 through 21 of each 21-day cycle.
    intervention Names
    1. Drug: Pemigatinib
    label
    Part 1: Continuous pemigatinib 13.5 mg QD
    type
    EXPERIMENTAL
  8. description
    Participants self-administered oral pemigatinib 20 mg QD on Days 1 through 21 of each 21-day cycle.
    intervention Names
    1. Drug: Pemigatinib
    label
    Part 1: Continuous pemigatinib 20 mg QD
    type
    EXPERIMENTAL
  9. description
    Participants self-administered oral pemigatinib 7.5 mg twice daily (BID) on Days 1 through 21 of each 21-day cycle.
    intervention Names
    1. Drug: Pemigatinib
    label
    Part 1: Continuous pemigatinib 7.5 mg BID
    type
    EXPERIMENTAL
  10. description
    Participants self-administered oral pemigatinib 10 mg BID on Days 1 through 21 of each 21-day cycle.
    intervention Names
    1. Drug: Pemigatinib
    label
    Part 1: Continuous pemigatinib 10 mg BID
    type
    EXPERIMENTAL
  11. description
    Participants self-administered oral pemigatinib 9 mg QD on a 2-weeks-on therapy and 1-week-off therapy schedule. The treatment cycle consisted of: Days 1 through 14: pemigatinib QD; Days 15 through 21: treatment break.
    intervention Names
    1. Drug: Pemigatinib
    label
    Part 2: Intermittent pemigatinib 9 mg QD
    type
    EXPERIMENTAL
  12. description
    Participants self-administered oral pemigatinib 13.5 mg QD on a 2-weeks-on therapy and 1-week-off therapy schedule. The treatment cycle consisted of: Days 1 through 14: pemigatinib QD; Days 15 through 21: treatment break.
    intervention Names
    1. Drug: Pemigatinib
    label
    Part 2: Intermittent pemigatinib 13.5 mg QD
    type
    EXPERIMENTAL
interventions
  1. arm Group Labels
    1. Part 1: Continuous pemigatinib 10 mg BID
    2. Part 1: Continuous pemigatinib 13.5 mg QD
    3. Part 1: Continuous pemigatinib 20 mg QD
    4. Part 1: Continuous pemigatinib 7.5 mg BID
    5. Part 1: Continuous pemigatinib 9 mg QD
    6. Part 1: Intermittent pemigatinib 1/2/4 mg QD
    7. Part 1: Intermittent pemigatinib 13.5 mg QD
    8. Part 1: Intermittent pemigatinib 20 mg QD
    9. Part 1: Intermittent pemigatinib 6 mg QD
    10. Part 1: Intermittent pemigatinib 9 mg QD
    11. Part 2: Continuous pemigatinib 13.5 mg QD
    12. Part 2: Continuous pemigatinib 20 mg QD
    name
    Pemigatinib
    other Names
    1. INCB054828
    type
    DRUG
  2. arm Group Labels
    1. Part 3: Gem/Cis/intermittent pemigatinib 13.5 mg
    2. Part 3: Gem/Cis/intermittent pemigatinib 9 mg
    name
    Gemcitabine
    type
    DRUG
  3. arm Group Labels
    1. Part 3: Pem/continuous pemigatinib 13.5 mg
    2. Part 3: Pem/intermittent pemigatinib 13.5 mg
    3. Part 3: Pem/intermittent pemigatinib 9 mg
    name
    Pembrolizumab
    type
    DRUG
  4. arm Group Labels
    1. Part 3: Doc/intermittent pemigatinib 13.5 mg
    name
    Docetaxel
    type
    DRUG
  5. arm Group Labels
    1. Part 3: Tras/intermittent pemigatinib 13.5 mg
    name
    Trastuzumab
    type
    DRUG
  6. arm Group Labels
    1. Part 3: Ref/continuous pemigatinib 13.5 mg
    2. Part 3: Ref/continuous pemigatinib 20 mg
    3. Part 3: Ref/continuous pemigatinib 9 mg
    name
    Retifanlimab
    other Names
    1. INCMGA00012
    type
    DRUG
  7. arm Group Labels
    1. Part 3: Gem/Cis/intermittent pemigatinib 13.5 mg
    2. Part 3: Gem/Cis/intermittent pemigatinib 9 mg
    name
    Cisplatin
    type
    DRUG
Study design
allocation
NON_RANDOMIZED
intervention Model
SEQUENTIAL
masking Info
masking
NONE
primary Purpose
TREATMENT
Enrollment
count
201
type
ACTUAL
Registered outcome plans (not posted results)
primary Outcomes
  1. description
    Adverse events were defined as the appearance of (or worsening of any pre-existing) undesirable sign(s), symptom(s), or medical condition(s) that occurred after a participant provided informed consent. Abnormal laboratory values or test results that occurred after informed consent constituted AEs only if they induced clinical signs or symptoms, were considered clinically meaningful, required therapy (e.g., hematologic abnormality that required transfusion), or required changes in the study drug(s). TEAEs were defined as adverse events either reported for the first time or the worsening of pre-existing events after the first dose of study drug and within 30 days of the last dose of study drug.
    measure
    Parts 1 and 2 Combined: Number of Participants With Any Treatment-emergent Adverse Event (TEAE)
    time Frame
    up to 763 days
  2. description
    Adverse events were defined as the appearance of (or worsening of any pre-existing) undesirable sign(s), symptom(s), or medical condition(s) that occurred after a participant provided informed consent. Abnormal laboratory values or test results that occurred after informed consent constituted AEs only if they induced clinical signs or symptoms, were considered clinically meaningful, required therapy (e.g., hematologic abnormality that required transfusion), or required changes in the study drug(s). TEAEs were defined as adverse events either reported for the first time or the worsening of pre-existing events after the first dose of study drug and within 30 days of the last dose of study drug.
    measure
    Part 3: Number of Participants With Any TEAE
    time Frame
    up to 869 days
  3. description
    E0 was defined as the Baseline serum concentration of phosphate.
    measure
    E0 Following Once Daily Dosing of Pemigatinib as Monotherapy in Parts 1 and 2
    time Frame
    predose on Days 1 and 14 of Cycle 1; anytime during visit on Day 1 of Cycle 2 and all subsequent cycles
  4. description
    EC50 was defined as the pemigatinib steady-state area under the plasma or serum concentration-time curve that increases 50% of serum phosphate.
    measure
    EC50 Following Once Daily Dosing of Pemigatinib as Monotherapy in Parts 1 and 2
    time Frame
    predose on Days 1 and 14 of Cycle 1; anytime during visit on Day 1 of Cycle 2 and all subsequent cycles
  5. description
    Emax was defined as the maximum degree of increasing of serum phosphate by pemigatinib.
    measure
    Emax Following Once Daily Dosing of Pemigatinib as Monotherapy in Parts 1 and 2
    time Frame
    predose on Days 1 and 14 of Cycle 1; anytime during visit on Day 1 of Cycle 2 and all subsequent cycles
  6. description
    Serum phosphate concentration was assessed throughout Parts 1 and 2.
    measure
    Highest Serum Phosphate Concentration Following Pemigatinib as Monotherapy in Parts 1 and 2
    time Frame
    predose on Days 1 and 14 of Cycle 1; anytime during visit on Day 1 of Cycle 2 and all subsequent cycles
secondary Outcomes
  1. description
    ORR was defined as the percentage of participants with a best overall response of complete response (CR) or partial response (PR), per Response Evaluation Criteria in Solid Tumors (RECIST) version 1.1, as determined by the investigator. CR: disappearance of all target and non-target lesions and no appearance of any new lesions. Any pathological lymph nodes (whether target or non-target) must have a reduction in the short axis to \<10 millimeters (mm). PR: complete disappearance or at least a 30% decrease in the sum of the diameters of target lesions, taking as a reference the baseline sum diameters, no new lesions, and no progression of non-target lesions.
    measure
    Part 2: Overall Response Rate (ORR)
    time Frame
    up to 126 days
  2. description
    ORR was defined as the percentage of participants with a best overall response of CR or PR, per RECIST version 1.1, as determined by the investigator. CR: disappearance of all target and non-target lesions and no appearance of any new lesions. Any pathological lymph nodes (whether target or non-target) must have a reduction in the short axis to \<10 millimeters (mm). PR: complete disappearance or at least a 30% decrease in the sum of the diameters of target lesions, taking as a reference the baseline sum diameters, no new lesions, and no progression of non-target lesions.
    measure
    Part 3: ORR
    time Frame
    up to 203 days
  3. description
    Cmax was defined as the maximum observed plasma concentration.
    measure
    Parts 1 and 2: Cmax After Once Daily Dosing of Pemigatinib as Monotherapy on Cycle 1 Day 1
    time Frame
    Part 1: predose; 0.5, 1, 2, 4, 6, and 8 hours post-dose post-dose on Cycle 1 Day 1. Part 2: predose on Cycle 1 Day 1
  4. description
    tmax was defined as the time to the maximum observed plasma concentration.
    measure
    Parts 1 and 2: Tmax After Once Daily Dosing of Pemigatinib as Monotherapy on Cycle 1 Day 1
    time Frame
    Part 1: predose; 0.5, 1, 2, 4, 6, and 8 hours post-dose post-dose on Cycle 1 Day 1. Part 2: predose on Cycle 1 Day 1
  5. description
    AUClast was defined as the area under the plasma or serum concentration-time curve from the time of dosing to the last measurable concentration.
    measure
    Parts 1 and 2: AUClast After Once Daily Dosing of Pemigatinib as Monotherapy on Cycle 1 Day 1
    time Frame
    Part 1: predose; 0.5, 1, 2, 4, 6, and 8 hours post-dose post-dose on Cycle 1 Day 1. Part 2: predose on Cycle 1 Day 1
  6. description
    AUC0-24 was defined as the area under the plasma or serum concentration-time curve from time 0 to 24 hours post-dose.
    measure
    Parts 1 and 2: AUC0-24 After Once Daily Dosing of Pemigatinib as Monotherapy on Cycle 1 Day 1
    time Frame
    Part 1: predose; 0.5, 1, 2, 4, 6, and 8 hours post-dose post-dose on Cycle 1 Day 1. Part 2: predose on Cycle 1 Day 1
  7. description
    Cmax was defined as the maximum observed plasma concentration.
    measure
    Parts 1 and 2: Cmax After Once Daily Dosing of Pemigatinib as Monotherapy on Cycle 1 Days 8 and 14 (Steady State)
    time Frame
    Part 1: predose on Cycle 1 Days 8 and 14; 0.5, 1, 2, 4, 6, and 8 hours post-dose on Cycle 1 Day 14. Part 2: predose on Cycle 1 Days 8 and 14; 0.5, 1, 2, 4, 6, and 8 hours post-dose on Cycle 1 Day 14
  8. description
    tmax was defined as the time to the maximum observed plasma concentration.
    measure
    Parts 1 and 2: Tmax After Once Daily Dosing of Pemigatinib as Monotherapy on Cycle 1 Days 8 and 14 (Steady State)
    time Frame
    Part 1: predose on Cycle 1 Days 8 and 14; 0.5, 1, 2, 4, 6, and 8 hours post-dose on Cycle 1 Day 14. Part 2: predose on Cycle 1 Days 8 and 14; 0.5, 1, 2, 4, 6, and 8 hours post-dose on Cycle 1 Day 14
  9. description
    t1/2 was defined as the apparent plasma terminal phase disposition half-life.
    measure
    Parts 1 and 2: t1/2 After Once Daily Dosing of Pemigatinib as Monotherapy on Cycle 1 Days 8 and 14 (Steady State)
    time Frame
    Part 1: predose on Cycle 1 Days 8 and 14; 0.5, 1, 2, 4, 6, and 8 hours post-dose on Cycle 1 Day 14. Part 2: predose on Cycle 1 Days 8 and 14; 0.5, 1, 2, 4, 6, and 8 hours post-dose on Cycle 1 Day 14
  10. description
    Cmin was defined as the minimum observed plasma concentration over the dose interval.
    measure
    Parts 1 and 2: Cmin After Once Daily Dosing of Pemigatinib as Monotherapy on Cycle 1 Days 8 and 14 (Steady State)
    time Frame
    Part 1: predose on Cycle 1 Days 8 and 14; 0.5, 1, 2, 4, 6, and 8 hours post-dose on Cycle 1 Day 14. Part 2: predose on Cycle 1 Days 8 and 14; 0.5, 1, 2, 4, 6, and 8 hours post-dose on Cycle 1 Day 14
  11. description
    AUC0-24 was defined as the area under the plasma or serum concentration-time curve from time 0 to 24 hours post-dose.
    measure
    Parts 1 and 2: AUC0-24 After Once Daily Dosing of Pemigatinib as Monotherapy on Cycle 1 Days 8 and 14 (Steady State)
    time Frame
    Part 1: predose on Cycle 1 Days 8 and 14; 0.5, 1, 2, 4, 6, and 8 hours post-dose on Cycle 1 Day 14. Part 2: predose on Cycle 1 Days 8 and 14; 0.5, 1, 2, 4, 6, and 8 hours post-dose on Cycle 1 Day 14
  12. description
    CL/F was defined as the apparent oral dose clearance.
    measure
    Parts 1 and 2: CL/F After Once Daily Dosing of Pemigatinib as Monotherapy on Cycle 1 Days 8 and 14 (Steady State)
    time Frame
    Part 1: predose on Cycle 1 Days 8 and 14; 0.5, 1, 2, 4, 6, and 8 hours post-dose on Cycle 1 Day 14. Part 2: predose on Cycle 1 Days 8 and 14; 0.5, 1, 2, 4, 6, and 8 hours post-dose on Cycle 1 Day 14
Full study description
brief Summary
The purpose of this study will be to evaluate the safety, tolerability, and pharmacological activity of pemigatinib in subjects with advanced malignancies. This study will have three parts, dose escalation (Part 1), dose expansion (Part 2) and combination therapy (Part 3).
Source references
references
  1. citation
    Subbiah V, Iannotti NO, Gutierrez M, Smith DC, Feliz L, Lihou CF, Tian C, Silverman IM, Ji T, Saleh M. FIGHT-101, a first-in-human study of potent and selective FGFR 1-3 inhibitor pemigatinib in pan-cancer patients with FGF/FGFR alterations and advanced malignancies. Ann Oncol. 2022 May;33(5):522-533. doi: 10.1016/j.annonc.2022.02.001. Epub 2022 Feb 14.
    pmid
    35176457
    type
    DERIVED
  2. citation
    Gong X, Ji T, Liu X, Chen X, Yeleswaram S. Evaluation of the clinical cardiac safety of pemigatinib, a fibroblast growth factor receptor inhibitor, in participants with advanced malignancies. Pharmacol Res Perspect. 2022 Feb;10(1):e00906. doi: 10.1002/prp2.906.
    pmid
    34951522
    type
    DERIVED
Source notices and limitations
    Discovery and provenance
    1. release id
      ctgov-registry-1336d216cbd1bbff780dac70
      edge id
      nct-edge-66d2ee5f1e9dcc2eb51f
      requested nct id
      NCT02393248
      primary nct id
      NCT02393248
      source kind
      ctgov_condition_query
      source record id
      Source null
      source file sha256
      2314ce01316b2d7044d298c6d25eda12e99cc5f44273bc75efed6cd5e03a8c14
      payload sha256
      648e372daaf1dc27746888c01c088def09b656ec5cb3a0c8903c4ec0a484d488
      payload
      clinical indication matching status
      condition_index_match_asserted_by_registry_not_reviewed
      end exclusive
      true
      id
      nct-edge-66d2ee5f1e9dcc2eb51f
      link basis
      returned_by_explicit_condition_and_posted_results_filter_query
      nct id
      NCT02393248
      occurrences
      1. context exact
        NCT02393248
        end
        11
        exact text
        NCT02393248
        start
        0
      offset unit
      unicode_code_points
      query cond
      Plasma Cell Neoplasms
      query disease state id
      ds-plasma-cell-neoplasms
      source file
      /Users/arunverma/Documents/ChatGPT/Cancer Statistics Website/research-data/2026-09-10/clinicaltrials-condition/round-0000/raw/cond-plasma-cell-neoplasms-000.json
      source file sha256
      2314ce01316b2d7044d298c6d25eda12e99cc5f44273bc75efed6cd5e03a8c14
      source json pointer
      /studies/294/protocolSection/identificationModule/nctId
      source kind
      ctgov_condition_query
      source record id
      Source null
      source string basis
      parsed_JSON_string_unmodified
      source string sha256
      3092fa5fb8ca7a0505df3e4565f01b8060c92df966c12034b9b603337bb89f92

    Preserved source evidence · Not medical advice